# Questions the Literature Can—and Cannot—Answer > FAQ — Recovery & Tissue Repair Research Peptides for a Canine Lens — Plain answers about BPC-157, TB-500, and GHK-Cu as Recovery & Tissue Repair research peptides, with the evidence gap for dogs clearly marked. **RESEARCH DESK / FAQ** Direct answers with species, study type, and uncertainty kept attached. ## What does BPC-157 do in the body? In laboratory models, BPC-157 influences blood-vessel signaling through VEGFR2, Akt, and endothelial nitric oxide, and it has also been linked to cell-migration and brain–gut pathways [4][7]. Rodent studies report repair-related outcomes in injured gastric and tendon tissue [5][6]. Those findings do not establish what BPC-157 does as treatment in a dog. The only beagle study here measured pharmacokinetics rather than clinical benefit [3]. Companion-animal use is not established; a licensed veterinarian should handle any dog-specific question. ## Is BPC-157 a growth hormone? No. BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence associated with human gastric juice. Some laboratory research discusses its interaction with growth-related signaling, but that does not make it growth hormone. Its main repair hypothesis in this corpus centers on angiogenesis and related pathways [4]. No canine clinical evidence establishes it as a treatment, and anything involving a dog belongs with a licensed veterinarian. ## Does BPC-157 work immediately? The evidence cannot support a reliable onset claim. Online timelines are **anecdotal, not clinical evidence**, and the controlled literature is dominated by animal and cell models. The tiny human safety pilot was not an efficacy study [1], while a recent review emphasizes the lack of rigorous large-scale human trials [2]. No canine clinical trial establishes whether BPC-157 works at all for a companion-animal condition, much less when. A licensed veterinarian should assess any dog needing recovery care. ## Does BPC-157 damage the liver? A two-person human safety pilot reported no measurable change in the liver biomarkers it assessed [1], but that sample cannot establish uncommon or long-term safety. It also says nothing definitive about dogs. Reviews describe the human evidence as extremely limited [2]. This corpus does not establish BPC-157 as safe for canine liver function or as treatment for any dog. Questions about liver disease, interactions, or exposure require a licensed veterinarian. ## What is TB-500? TB-500 commonly refers to a synthetic seven-amino-acid fragment containing the LKKTETQ actin-binding motif of thymosin beta-4. It is not the same as the full 43-amino-acid parent protein. Most regenerative efficacy research summarized here concerns full-length thymosin beta-4 [10][12]. No controlled canine clinical trial in this corpus establishes the TB-500 fragment as safe or effective, so any dog-specific discussion belongs with a licensed veterinarian. ## What does TB-500 stand for and what does TB stand for in TB-500? The name is used for a synthetic fragment related to **thymosin beta-4**, which supplies the “TB” association. The label can obscure a crucial difference: TB-500 is the short Ac-LKKTETQ fragment, while much published work tested full-length thymosin beta-4. That mismatch matters more than expansion of the abbreviation. Neither the name nor veterinary-context usage establishes companion-animal efficacy. A licensed veterinarian should address any question involving a dog. ## What is TB-500 used for in research? The surrounding thymosin beta-4 literature examines actin binding, cell migration, angiogenesis, inflammation, scarring, and experimental repair [10][12]. A review of unapproved musculoskeletal peptides notes favorable animal-model signals but scarce rigorous human safety data [8]. Evidence for the full parent protein should not be silently assigned to the TB-500 fragment. There is no established companion-animal use in this corpus, and no veterinary protocol is offered here. ## Does TB-500 work for muscle tears and recovery from exercise? The source set cannot establish that claim for people or dogs. Human community recovery stories are **anecdotal, not clinical evidence**. The available research relies heavily on full-length thymosin beta-4, animal models, and mechanism studies rather than controlled trials of the TB-500 fragment [8][10][12]. No canine clinical trial demonstrates repair of a muscle tear or faster functional recovery. An injured dog needs examination by a licensed veterinarian. ## What does a GHK-Cu peptide do? GHK-Cu binds copper and is studied in relation to extracellular-matrix remodeling, collagen and elastin biology, antioxidant signaling, gene expression, and topical skin repair [14][16]. Human evidence is concentrated in relatively small topical skin or hair studies [13][15]. These findings do not establish systemic repair or treatment in dogs. Companion-animal use is not established, and a licensed veterinarian should evaluate any canine skin or tissue concern. ## What is GHK-Cu and how does it work? GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper. It can carry copper and influence cell signals involved in matrix production and remodeling [16]. Gene-expression studies report broad pathway changes, but those are mechanistic findings rather than proof of clinical healing [14]. Native GHK also crosses the skin barrier poorly, making formulation important [13][17]. No canine trial here establishes benefit or safety; dog-specific decisions belong with a licensed veterinarian. ## Is GHK-Cu peptide really anti-aging? “Anti-aging” is broader than the evidence. Small topical human studies and reviews report changes in skin appearance and procollagen-related measures [13][16], but those findings do not prove whole-body rejuvenation. A combination hair study cannot isolate GHK-Cu’s effect [15]. Nothing in this corpus establishes an anti-aging treatment for dogs or other companion animals. A veterinarian should assess any specific canine skin, coat, wound, or health concern. ## What is the difference between GHK and GHK-Cu? GHK is the three-amino-acid peptide; GHK-Cu is that peptide coordinated to a copper ion. Copper binding is central to many proposed matrix and signaling effects, so the two forms should not be treated as interchangeable [16]. Delivery and stability also affect behavior [13][17]. Neither form has an established companion-animal treatment role in this corpus. Any proposed use on or in a dog requires discussion with a licensed veterinarian. --- An independent veterinary-lens reading of repair-peptide literature—human and model evidence made legible, never recast as care for a dog.